Relationship between decrease in ambulatory blood pressure and heart rate variability due to the effects of taking olmesartan medoxomil

Clinical Drug Investigation

Volumn 29, Issue 4, 2009, Pages 257-264

  Furukawa, Taiji ^a   Hatsuno, Taketo ^a   Ueno, Yasunari ^a   Nagaoka, Kensuke ^a   Watari, Yuji ^a   Yamakawa, Takeshi ^a   Sagawa, Toshio ^a   Isshiki, Takaaki ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANDESARTAN HEXETIL; OLMESARTAN;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE MONITORING; CLINICAL ARTICLE; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG WITHDRAWAL; ESSENTIAL HYPERTENSION; FEMALE; HEART RATE; HEART RATE VARIABILITY; HOLTER MONITORING; HUMAN; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE WAVE; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; IMIDAZOLES; JAPAN; MALE; TETRAZOLES; TREATMENT OUTCOME;

EID: 62949182827     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200929040-00004     Document Type: Article

References (17)

1. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial. The Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355 (9215): 1582-7
2. Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345 (23): 1667-75
3. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362 (9386): 759-66
4. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004; 26 Suppl. A: A33-7
5. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Invest 2006; 26 (4): 185-93
6. Hiromichi S. Examination of the clinical usefulness of various angiotensin receptor blockers in regard to treatment of hypertension that accompanies nephropathy. Prog Med 2006; 26: 1669-75
7. Taiji S, Misako T, Tatsuya O, et al. Examination with regard to the effects of olmesartan on hypertension patients with diabetic complications. Prog Med 2006; 26: 475-9
8. Shinji T, Masato O, Satoshi M, et al. Blood pressure survey of essential hypertension patients in the early morning, ambulatory period and at night: ATOM Research. Pharmacol Treat 2004; 32: 481-6
9. Mitera T, Saitou M, Satou T, et al. 24-hour blood pressure and time course of heart rate variability changes in regard to 3 kinds of dihydropyridine-type Ca2+ channel blockers. Electrocardiogram 2001; 21: 481-90
10. Keishi A, Iwao K, Yutaka I, et al. Effects of the long-acting type Ca blocker balnidipine hydrochloride on blood pressure circadian rhythm: large-scale clinical trial J-MUBA. Final results. Ther Res 1999; 20: 2697-713
11. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004; 6 (10): 569-77
12. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001; 3 (5): 283-91, 318
13. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents: olmesartan medoxomil versus antihypertensives. J Hypertens Suppl. 2001; 19 (1): S49-56
14. Miura S, Fujino M, Saku K. Angiotensin II receptor blocker as an inverse agonist: a current perspective. Curr Hypertens Rev 2005; 1: 115-21
15. Furberg CD, Psaty BM, Meyer JV. Nifedipine: dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92 (5): 1326-31
16. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension 2002; 39 (1): 10-5
17. Laurent S, Katsahian S, Fassot C, et al. Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke 2003; 34 (5): 1203-6